Ceftobiprole: a new broad spectrum cephalosporin

Bibliography

• Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007;298(15):1763-71
   PubMed Web of Science ®Google Scholar
• Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002;34(5):634-40
   PubMed Web of Science ®Google Scholar
• Hebeisen P, Heinze-Krauss I, Angehrn P, et al. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother 2001;45(3):825-36
   PubMed Web of Science ®Google Scholar
• Sorbera L, Castaner J, Castaner R. Ceftobiprole/ceftobiprole medocaril. Drugs Future 2005;30(1):11-22
   Web of Science ®Google Scholar
• de Lencastre H, de Jonge BL, Matthews PR, Tomasz A. Molecular aspects of methicillin resistance in Staphylococcus aureus. J Antimicrob Chemother 1994;33(1):7-24
   PubMed Web of Science ®Google Scholar
• Lim D, Strynadka NC. Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus. Nat Struct Biol 2002;9(11):870-6
   PubMedGoogle Scholar
• Livermore DM. Can beta-lactams be re-engineered to beat MRSA? Clin Microbiol Infect 2006;12(Suppl 2):11-6
   PubMed Web of Science ®Google Scholar
• Davies TA, Page MG, Shang W, et al. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob Agents Chemother 2007;51(7):2621-4
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Roos B, Schleimer M, et al. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 2004;48(7):2570-5
   PubMed Web of Science ®Google Scholar
• Zeftera. Janssen-Ortho, Inc. Toronto, Ontario, 2008. Available from: www. janssen-ortho.com/JOI/pdf_files/Zeftera_E.pdf [Last accessed 4 April 2009]
   Google Scholar
• Jimidar I, Vermeersch H, Tinke A, et al. Stability of ceftobiprole medocaril powder for injection in common fluids and containers [abstract P-54E]. American Society of Health-System Pharmacists; Seattle, WA, 8-11 June 2008
   Google Scholar
• Drusano G, Rodvold K, Lodise T, et al. Penetration of ceftobiprole into epithelial lining fluid as deermined by population pharamcokinetic modeling and circulation of AUCELF/AUCPlasma ratio in healthy volunteers [abstract A-1902]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, 25–28 October 2008
   Google Scholar
• Schmitt-Hoffmann A, Nyman L, Roos B, et al. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 2004;48(7):2576-80
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Murthy B, Strauss RS, et al. Pharmacokinetics (PK) of multiple infusions of ceftobiprole (1000 mg every 8 hours) in healthy volunteers [abstract A-1943]. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology; San Francisco, CA, September 27–30, 2006
   Google Scholar
• Lodise TP Jr, Pypstra R, Kahn JB, et al. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob Agents Chemother 2007;51(7):2378-87
   PubMed Web of Science ®Google Scholar
• Schmitt-hoffmann AH, Roos B, Heep M, et al. Influence of gender on the pharmacokinetics of BAL9141 after intravenous infusion of prodrug BAL5788. Clin Microbiol Infect 2004;10(Suppl 3):276-7
   Google Scholar
• Roos B, Schmitt-Hoffmann A, Schleimer M, et al. Safety and pharmacokinetics of BAL5788 in healthy subjects with normal or impaired renal function [abstract A-23]. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology; Chicago, IL, 14-17 Sep 2003
   Google Scholar
• Murthy B, Skee D, Vaccaro N, et al. An open-label pharmacokinetic study of ceftobiprole in health subjects and subjects with end-stage renal disease receiving hemodialysis. [abstract A-1896]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, 25-28 October 2008
   Google Scholar
• Murthy B, Schmitt-Hoffmann A. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin Pharmacokinet 2008;47(1):21-33
   PubMed Web of Science ®Google Scholar
• Andes D, Craig WA. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother 2006;50(4):1376-83
   PubMed Web of Science ®Google Scholar
• Drusano GL. Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’. Nat Rev Microbiol 2004;2(4):289-300
   PubMed Web of Science ®Google Scholar
• Mouton JW, Schmitt-Hoffmann A, Shapiro S, et al. Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob Agents Chemother 2004;48(5):1713-8
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Citron DM, Merriam CV, et al. In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections. Antimicrob Agents Chemother 2006;50(11):3959-62
   PubMed Web of Science ®Google Scholar
• Blondeau JM, Yaschuk Y, Suter M, Vaughan D. In-vitro susceptibility of 1982 respiratory tract pathogens and 1921 urinary tract pathogens against 19 antimicrobial agents: a Canadian multicentre study. Canadian Antimicrobial Study Group. J Antimicrob Chemother 1999;43(Suppl A):3-23
   PubMed Web of Science ®Google Scholar
• Wootton M, Bowker KE, Holt HA, MacGowan AP. BAL 9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials. J Antimicrob Chemother 2002;49(3):535-9
   PubMed Web of Science ®Google Scholar
• Yun H, Ellis M, Jorgensen J. Activity of ceftobiprole against community-associtaed methicillin reistant Staphylococcus aureus isolates recently recovered from US military trainees. Diagn Microbiol Infect Dis 2007;59(4):463-66
   PubMed Web of Science ®Google Scholar
• Jones RN, Deshpande LM, Mutnick AH, Biedenbach DJ. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother 2002;50(6):915-32
   PubMed Web of Science ®Google Scholar
• Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005;49(10):4210-9
   PubMed Web of Science ®Google Scholar
• Rouse MS, Steckelberg JM, Patel R. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection. Diagn Microbiol Infect Dis 2007;58(3):363-5
   PubMed Web of Science ®Google Scholar
• Pillar CM, Aranza MK, Shah D, Sahm DF. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin. J Antimicrob Chemother 2008;61(3):595-602
   PubMed Web of Science ®Google Scholar
• Deshpande LM, Jones RN. Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. Clin Microbiol Infect 2003;9(11):1120-4
   PubMed Web of Science ®Google Scholar
• Chambers HF. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005;49(3):884-8
   PubMed Web of Science ®Google Scholar
• Lin G, Appelbaum PC. Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis. Diagn Microbiol Infect Dis 2008;60(2):233-5
   PubMed Web of Science ®Google Scholar
• Kosowska K, Hoellman DB, Lin G, et al. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005;49(5):1932-42
   PubMed Web of Science ®Google Scholar
• Arias CA, Singh KV, Panesso D, Murray BE. Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model. J Antimicrob Chemother 2007;60(3):594-8
   PubMed Web of Science ®Google Scholar
• Issa NC, Rouse MS, Piper KE, et al. In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria. Diagn Microbiol Infect Dis 2004;48(1):73-5
   PubMed Web of Science ®Google Scholar
• Bogdanovich T, Clark C, Ednie L, et al. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob Agents Chemother 2006;50(6):2050-7
   PubMed Web of Science ®Google Scholar
• Ednie L, Shapiro S, Appelbaum PC. Antianaerobe activity of ceftobiprole, a new broad-spectrum cephalosporin. Diagn Microbiol Infect Dis 2007;58(1):133-6
   PubMed Web of Science ®Google Scholar
• Queenan AM, Shang W, Kania M, et al. Interactions of ceftobiprole with beta-lactamases from molecular classes A to D. Antimicrob Agents Chemother 2007;51(9):3089-95
   PubMed Web of Science ®Google Scholar
• Entenza JM, Hohl P, Heinze-Krauss I, et al. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob Agents Chemother 2002;46(1):171-7
   PubMed Web of Science ®Google Scholar
• Rouse MS, Hein MM, Anguita-Alonso P, et al. Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia. Diagn Microbiol Infect Dis 2006;55(4):333-6
   PubMed Web of Science ®Google Scholar
• Banerjee R, Gretes M, Basuino L, et al. In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008;52(6):2089-96
   PubMed Web of Science ®Google Scholar
• Heep M, Harsch M, Querner S, et al. Ceftobiprole (BAL5788), the first of a new class of anti-MRSA cephalosporins-microbiological results from a Phase II study in cSSSI [abstract L-361]. 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting; Washington D.C., October 30–November 2, 2004
   Google Scholar
• Noel GJ, Strauss RS, Amsler K, et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 2008;52(1):37-44
   PubMed Web of Science ®Google Scholar
• Noel GJ, Bush K, Bagchi P, et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008;46(5):647-55
   PubMed Web of Science ®Google Scholar
• Nicholson SC, Strauss RS, Michiels B, et al. Efficacy of ceftobiprole compared to ceftriaxone ± linezolid for the treatment of subjects hospitalized with community-acquired pneumonia [abstract C-16]. The American Thoracic Society International Conference; Toronto, Canada; 16–21 May 2008
   Google Scholar
• Noel GL, Strauss RS, Shah A, Bagchi P, and the BAP00248/307 Study Group. Ceftobiprole versus ceftazidime combined with linezolid for treatment of patients with nosocomial pneumonia [abstract K-486]. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting; Washington, DC; October 26–29 2008
   Google Scholar
• Roberts A, Lipman J. Pharmacokinetics issues for antibiotics in the critically ill patient. Crit Care Med 2009;37:840-51
   PubMed Web of Science ®Google Scholar
• Hoffman-Roberts HL, E CB, Mitropoulos IF. Investigational new drugs for the treatment of resistant pneumococcal infections. Expert Opin Investig Drugs 2005;14(8):973-95
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41(10):1373-406
   PubMed Web of Science ®Google Scholar
• King MD, Humphrey BJ, Wang YF, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006;144(5):309-17
   PubMed Web of Science ®Google Scholar
• Moellering RC Jr. The growing menace of community-acquired methicillin-resistant Staphylococcus aureus. Ann Intern Med 2006;144(5):368-70
   PubMed Web of Science ®Google Scholar
• Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis 2007;44(6):777-84
   PubMed Web of Science ®Google Scholar
• Szumowski JD, Cohen DE, Kanaya F, Mayer KH. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 2007;51(2):423-8
   PubMed Web of Science ®Google Scholar
• Rennie RP, Jones RN, Mutnick AH. Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis 2003;45(4):287-93
   PubMed Web of Science ®Google Scholar
• Bogdanovich T, Bozdogan B, Applebaum PC. Resistance selection studies on staphylococci with ceftobiprole (BAL9141) [abstract E-2018]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 30–November 2, 2004
   Google Scholar
• Heller S, Marrer E, Page MGP, et al. Development of endogenous resistance by staphylococci to BAL9141 and comparators [abstract P675]. 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic, May 1– 4, 2004
   Google Scholar
• Queenan AM, Bush K. Ceftobiprole: effect on AmpC β-lactamase induction and resistance frequency in gram-negative bacteria [abstract C1-55]. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, December 16–19, 2005
   Google Scholar